NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 370
(Total Views: 366)
Posted On: 05/14/2021 6:35:52 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2021 Results, Provides Clinical Update and Business Outlook
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided a clinical update and business outlook and released its financial results for the quarter ended March 31, 2021. “2021 is poised to be an exciting year for the company. Throughout the first quarter, we have made continued development and regulatory progress on all fronts and are committed to driving our novel treatments forward as expeditiously as possible with the primary focus on our Berubicin program to improve patient outcomes for GBM,” said John Climaco, CEO of CNS Pharmaceuticals. “We are looking forward to the near-term initiation of patient enrollment in our potentially pivotal trial, which we believe will be a catalytic event in the evolution of CNS Pharmaceuticals as it transitions us into a late-stage clinical company. We look forward to gaining additional insight into Berubicin’s potential to unlock powerful benefits in the fight against GBM, which remains as one of the most aggressive types of brain cancer. We believe there is significant potential to unlock shareholder value over the course of the next 18 months and we look forward to providing continued updates and driving momentum.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided a clinical update and business outlook and released its financial results for the quarter ended March 31, 2021. “2021 is poised to be an exciting year for the company. Throughout the first quarter, we have made continued development and regulatory progress on all fronts and are committed to driving our novel treatments forward as expeditiously as possible with the primary focus on our Berubicin program to improve patient outcomes for GBM,” said John Climaco, CEO of CNS Pharmaceuticals. “We are looking forward to the near-term initiation of patient enrollment in our potentially pivotal trial, which we believe will be a catalytic event in the evolution of CNS Pharmaceuticals as it transitions us into a late-stage clinical company. We look forward to gaining additional insight into Berubicin’s potential to unlock powerful benefits in the fight against GBM, which remains as one of the most aggressive types of brain cancer. We believe there is significant potential to unlock shareholder value over the course of the next 18 months and we look forward to providing continued updates and driving momentum.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)